Medical network - on July 26, according to statistics, since this year, as of July 25, A shares biological medicine industry A total of 121 listed companies released the 213 merger, acquisition and reorganization matters, relating to the amount of about 42.35 billion yuan. There are 164 mergers and acquisitions in the process, three mergers and acquisitions failed, and 46 mergers and acquisitions have been completed.
Compared with the hundreds of billions of mergers and acquisitions in the a-share industry, the value has shrunk dramatically in 2017. According to statistics, in accordance with the date of the first release of merger, acquisition and reorganization plan, 2015 a-share biological medicine industry scale of merger, acquisition and reorganization reached its peak, about 113.6 billion yuan, the sharp decline in the value of 2016 to 2016 yuan. Nearly seven months into 2017, the number of mergers and acquisitions in the pharmaceutical industry has been just 37 per cent of 2015.
, Goldman sachs executive director qu rong is on the east, according to the reporter said in an interview: "biological medicine industry mergers and acquisitions is a few years ago, to reconstruct the target have been digging more fully, the rest of the opportunity also is less, and now let go of the IPO, it also brings to the merger, acquisition and reorganization the new challenge."
M&a slowdown
Data show that this year, only eight pharmaceutical bio-listed companies have seen more than 1 billion yuan in mergers and acquisitions.
Among them, the merger and reorganization of human fu medicine is larger. The two acquisitions were announced on May 27, involving the acquisition of Ansell Ltd. Subordinate to the global (except China), all six subsidiaries of the company and the equity of the company and the equity of the company. On June 13, the medicine and CSL BEHRING ASIA PACIFIC LTD. (Chinese name called "jetter belin (ASIA PACIFIC) co., LTD") signed the share purchase agreement, for about $351.8 million will hold a wholly owned subsidiary of wuhan zhongyuan rhett biological products co., LTD. 80% stake to jet belin (ASIA PACIFIC) co., LTD. On June 27, people f medicine is a wholly owned subsidiary f the United States and the BLUE RIDGE HOLDING (CAYMAN) LIMITED signed a mutual investment and shareholders agreement, to participate in setting up in the United States share company AGIC - HUMANWELL BLUE RIDGE (US) LIMITED, used in mergers and acquisitions RiteDose Holdings, Inc. (hereinafter referred to as the "RiteDose") 100% stake. It is understood that RiteDose is a maker of single-dose sterile chemicals used in a Blow - Fill - Seal technology in the United States.
Method group has launched the subsidiary d star enterprise equity transfer, industrial and commercial registration of change "announcement, the company will sell its holdings of d star industrial co., LTD. 100% stake in zhuhai zhuhai hengqin d create wealth investment co., LTD, deal price is about 4.552 billion yuan.
The temple of heaven creatures in the first half of this year also completed the material assets reorganization, at present, the material assets reorganization has been completed to sell assets in Beijing north raw research biological products co., LTD. 100% stake, and changchun qi jian biological products co., LTD. 51% stake in the transfer procedures and related industrial and commercial registration; At the same time, it has completed the purchase of 80 % of the ownership transfer procedures and related business registration and registration of foreign-invested enterprises. It is understood that the total value of this asset restructuring transaction is over 2.1 billion yuan.
In addition, some listed companies have ended mergers and acquisitions. The company announced late on July 24 that it plans to terminate its planned major asset restructuring. According to the company, according to the material assets reorganization matters for the company to buy all or part of the stake in the target company, target company belongs to the pharmaceutical related industries, the reorganization of the other unrelated third parties, for the company does not constitute a related party transactions, also won't lead to control changes. But because the two sides have failed to agree on the important terms of the deal, it is not expected to form a concrete and feasible plan to continue the restructuring in a short time. The listed company then decided to terminate the major asset restructuring.
While some listed companies are continuing to push ahead with mergers and acquisitions, the premium rate seen from corporate acquisitions has diminished in the past.
In addition, the reporter through private data (the report data source mainly through vc institutions) query, from 2012 to 2016, biological medicine industry has been expanding its m&a, including about 252 2016 mergers and acquisitions, scale up to 85.4 billion yuan, in the first half of this year, biological medicine industry mergers and acquisitions size, about 97, m&a scale is about 32.2 billion yuan, both in number of mergers and acquisitions and mergers and acquisitions are less than half of 2016.
IPO acceleration, new three board active
In the view of qu jae-yong, future mergers and acquisitions of pharmaceutical biological industries, especially "the mode of non-listing of listed companies" will be reduced. "First, high quality mark enterprise less and less, and some companies also think independent public; second, this batch of think it is not listed on the there will always be part of the city, the final will be mergers and acquisitions, but the future not necessarily will become the mainstream; third, the new listed companies more and more, the future will also be a m&a targets".
The number of pharmaceutical biotech companies listed this year is on track to record a record high, according to data.
According to the statistics, there are 257 listed companies of pharmaceutical bio-listed companies as of now, with more companies listed in 2010 and 2011, 25 and 26 respectively. So far this year, as of July 25, A total of 24 pharmaceutical biotechnology companies have listed.
In the listed companies in the 24, according to shenyin wanguo industry categories, such as WeiXinKang, Mr Cheung pharmaceutical seven chemical pharmaceutical enterprises, KTS seven biological products companies such as biological, cape, the health, is the sea creatures such as 5 medical instrument companies, 1 medicine commercial companies - saint pharmaceutical, 1 medical services companies - genomics. These listed companies is about 11.26 billion yuan worth of starting to raise money, one day the pharmacy, the more than 1 billion yuan worth of biological starting to raise money, and starting conde creatures raised about 138 million yuan. As of July 25, the total market value of the two listed companies of huarong gene and kangtai biology has exceeded 10 billion yuan.
"The acceleration of ipos has also led to more companies opting for a separate listing." If there is no special case, the number of pharmaceutical companies listed this year could be at a record high, an industry source told reporters.
In addition, the merger and reorganization of the merger and acquisition of A share in the same time, the merger and reorganization of the new third board pharmaceutical industry is becoming more and more active. Statistics show that in 2015, 2016, the new three board pharmaceutical biotechnology industries of merger, acquisition and reorganization of the total amount is 880 million yuan and 3.878 billion yuan respectively, and since 2017, as of July 25, the new three board pharmaceutical biotechnology industries of merger, acquisition and reorganization scale has reached 10.51 billion yuan.
The merger and acquisition of eight listed companies is worth more than 100 million yuan. Or whole pharmaceutical industry, according to the announcement on April 21, the company by way of issuing shares, wuxi to Shanghai issued 12.850862 million shares to buy the PDS department all assets and liabilities, issuing shares price of 118.28 yuan/share, deal price is RMB 1.52 billion. In January, the company announced that it would buy a 100% stake in hangzhou australiano biotechnology co., ltd. in a targeted share offering, at a price of 244 million yuan. |
